ACP’s updated guideline reshapes the treatment landscape for osteoporosis and low bone mass. This concise, physician-focused white paper distills the changes and what they mean for your patients.
What you’ll learn:
- The big shift: Bisphosphonates as the preferred first-line therapy.
- Treatment pathways for very high-risk patients.
- Where denosumab fits — and when not to use it.
- Clinical pearls from Drs. Kashif Piracha and Katherine Wysham.